<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03230071</url>
  </required_header>
  <id_info>
    <org_study_id>P2017-03-BDY-03-V03</org_study_id>
    <nct_id>NCT03230071</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of TMBCZG in Mild to Moderate Vascular Dementia</brief_title>
  <official_title>Efficacy and Safety of Twice Daily TMBCZG in Mild to Moderate Vascular Dementia: Randomized, Double Blind, Parallel Group, Placebo Controlled, Multicenter Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dongzhimen Hospital, Beijing</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Union pharmaceutical factory II</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Compete Medical Technology Development Co. Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dongzhimen Hospital, Beijing</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will be a 24-week multicentre, double-blind, placebo-controlled phase Ⅱa trial with&#xD;
      4 treatment arms in China. Participants aged 55-80 years will be randomized to TMBCZG-high&#xD;
      dose(84mg per day), TMBCZG- medium dose(56mg per day), TMBCZG- low dose(28mg per day) or to&#xD;
      placebo. The primary endpoint will be VADAS-Cog and CDR-SB. Secondary outcomes included&#xD;
      changes in MMSE and ADL. Patients' safety will be assessed by recording of adverse events,&#xD;
      clinical examinations, electrocardiography and laboratory tests. The patients, caregivers,&#xD;
      and investigators will be blinded to the treatment allocations.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 28, 2017</start_date>
  <completion_date type="Actual">February 5, 2021</completion_date>
  <primary_completion_date type="Actual">August 22, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vascular Dementia Assessment Scale-cognitive subscale(VADAS-Cog)</measure>
    <time_frame>baseline, 4-week, 12-week, 24-week and 28-week.</time_frame>
    <description>Change from baseline to end of double-blind treatment of VADAS-Cog.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Dementia Rating-Sum of Boxes (CDR-SB)</measure>
    <time_frame>baseline, 4-week, 12-week, 24-week and 28-week.</time_frame>
    <description>Change from baseline to end of double-blind treatment of CDR-SB.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mini-Mental State Examination (MMSE)</measure>
    <time_frame>baseline, 4-week, 12-week, 24-week and 28-week.</time_frame>
    <description>Change from baseline to end of double-blind treatment of MMSE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activities of daily living (ADL)</measure>
    <time_frame>baseline, 4-week, 12-week, 24-week and 28-week.</time_frame>
    <description>Change from baseline to end of double-blind treatment of ADL.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">160</enrollment>
  <condition>Vascular Dementia</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo identified to TMBCZG,0.1g per pill which contains 0mg TMBCZG，3 pills per time, 2 times per day for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TMBCZG-high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TMBCZG, 0.1g per pill which contains 14mg TMBCZG, 3 pills per time, 2 times per day for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TMBCZG-medium dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TMBCZG( 0.1g per pill which contains 14mg TMBCZG) and placebo identified to TMBCZG(0.1g per pill which contains 0mg TMBCZG), 2 TMBCZG pills and 1 placebo pill per time, 2 times per day for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TMBCZG-low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TMBCZG( 0.1g per pill which contains 14mg TMBCZG) and placebo identified to TMBCZG(0.1g per pill which contains 0mg TMBCZG), 1 TMBCZG pills and 2 placebo pill per time, 2 times per day for 24 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TMBCZG</intervention_name>
    <description>0.1g per pill which contains 14mg TMBCZG</description>
    <arm_group_label>TMBCZG-high dose</arm_group_label>
    <arm_group_label>TMBCZG-low dose</arm_group_label>
    <arm_group_label>TMBCZG-medium dose</arm_group_label>
    <other_name>TianMaBianChunZhiGanPian</other_name>
    <other_name>TianMaYouJiDuoSuanBianZhiGanPian(TMYJDSBZG)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>0.1g per pill which contains 0mg TMBCZG</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>TMBCZG-low dose</arm_group_label>
    <arm_group_label>TMBCZG-medium dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients meeting the clinical diagnosis of probable vascular dementia(VaD) established&#xD;
             according to the National Institute of Neurological Disorders and Stroke and the&#xD;
             Association Internationale pour la Recherche et l'Enseignement en Neurosciences&#xD;
             (NINDS-AIREN)were eligible to participate:&#xD;
&#xD;
               1. Dementia defined by clinical core criteria,&#xD;
&#xD;
               2. Cerebrovascular disease, defined by history of stroke, as well as multiple basal&#xD;
                  ganglia and white matter lacunes, or extensive periventricular white matter&#xD;
                  lesions( excluded medial temporal lobe atrophy or other special image),&#xD;
&#xD;
               3. A relationship between dementia and Cerebrovascular disease, manifested or&#xD;
                  inferred by the presence of one or more of the following: (a) onset of dementia&#xD;
                  within 3 months following a recognized stroke; (b) abrupt deterioration in&#xD;
                  cognitive functions; or fluctuating, stepwise progression of cognitive deficits.&#xD;
&#xD;
          -  Mild to Moderate Dementia with MMSE score of ≤26 and ≥11;&#xD;
&#xD;
          -  Aged ≥55 and ≤80 years old in both gender;&#xD;
&#xD;
          -  Weighing of ≥45kg and ≤90kg;&#xD;
&#xD;
          -  Adequate vision and hearing ability to complete all study tests;&#xD;
&#xD;
          -  With a stable caregiver.&#xD;
&#xD;
          -  Have a certain level of language competence (can read simple articles and write simple&#xD;
             sentences);&#xD;
&#xD;
          -  Informed consent, signed informed consent by legal guardian.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A medical history of other dementia types, like mixed dementia, Alzheimer's disease,&#xD;
             frontotemporal dementia, Parkinson's disease dementia, dementia with Lewy bodies,&#xD;
             Huntington disease, et al;&#xD;
&#xD;
          -  Subdural hematoma, traffic hydrocephalus, brain tumor, thyroid disease,vitamin&#xD;
             deficiency or other diseases which can lead to cognitive impediment;&#xD;
&#xD;
          -  Major depression (HAMD≥17) or major anxious(HAMA≥12);&#xD;
&#xD;
          -  Subject can't complete related test due to severe neurologic deficits, such as&#xD;
             hemiplegia, aphasia, audio-visual disorder and so forth;&#xD;
&#xD;
          -  Severe cardiovascular disease(severe arrhythmia, myocardial infarction within 3&#xD;
             months, New York Heart Association Functional Classification III-IV, systolic&#xD;
             pressure≥180mmHg or ≤90mmHg);&#xD;
&#xD;
          -  Severe liver or kidney dysfunction (alanine aminotransferase or aspartate transaminase&#xD;
             is more than 1.5 times the upper limit of normal, or serum creatinine is more than the&#xD;
             upper limit of normal);&#xD;
&#xD;
          -  Uncontrolled diabetes(glycosylated hemoglobin is more than 2 times the upper limit of&#xD;
             normal);&#xD;
&#xD;
          -  Asthma, chronic obstructive pulmonary disease, multiple neuritis, myasthenia gravis&#xD;
             and muscle atrophy;&#xD;
&#xD;
          -  Severe indigestion, gastrointestinal obstruction, gastric and duodenal ulcers and&#xD;
             other gastrointestinal disorders that can affect drug absorption;&#xD;
&#xD;
          -  A medical history of epileptic history, glaucoma, alcoholism, or psycho-substance&#xD;
             abuse;&#xD;
&#xD;
          -  Subject has been taking cholinesterase inhibitors, memantine, nimodipine or herbal&#xD;
             medicine with function of improving cognition in the past one month;&#xD;
&#xD;
          -  Use of sympathomimetic or antihistamines drugs within 48h before assessment;&#xD;
&#xD;
          -  Allergic constitution or allergic reactions to experimental drug;&#xD;
&#xD;
          -  According to the assessment of the investigator, subject cann't complete the study due&#xD;
             to poor compliance or other reasons;&#xD;
&#xD;
          -  Subject is participating in other clinical trials or participated in the past 1 month.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>JinZhou Tian, MD,PhD</last_name>
    <role>Study Director</role>
    <affiliation>Dongzhimen Hospital, Beijing University of Chinese Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dongzhimen Hospital ,Beijing University of Chinese Medicine</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100700</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>July 24, 2017</study_first_submitted>
  <study_first_submitted_qc>July 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2017</study_first_posted>
  <last_update_submitted>February 28, 2021</last_update_submitted>
  <last_update_submitted_qc>February 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dongzhimen Hospital, Beijing</investigator_affiliation>
    <investigator_full_name>Jinzhou Tian</investigator_full_name>
    <investigator_title>vice-president</investigator_title>
  </responsible_party>
  <keyword>Herbal therapy</keyword>
  <keyword>Randomized controlled trial</keyword>
  <keyword>Vascular Dementia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Dementia, Vascular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

